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Featured Article
NPT088 reduces both amyloid-b and tau pathologies in
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aNeuroPhage Pharmaceuticals, Inc., Cambridge, MA, USA
bDepartment of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA
cDepartment of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel
Abstract Introduction: Alzheimer’s disease (AD) is characterized by appearance of both extracellular senile
plaques and intracellular neurofibrillary tangles, comprised of aggregates of misfolded amyloid-b
(Ab) and hyper-phosphorylated tau, respectively. In a previous study, we demonstrated that g3p, a
capsid protein from bacteriophage M13, binds to and remodels misfolded aggregates of proteins
that assume an amyloid conformation. We engineered a fusion protein (“NPT088”) consisting of
the active fragment of g3p and human-IgG1-Fc.
Methods: Aged Tg2576 mice or rTg4510 mice received NPT088 weekly via IP injection. Cognitive
and/or functional motor endpoints were monitored during dosing. Pathology was quantified biochem-
ically and immunohistochemically.
Results: NPT088-lowered Ab plaque and improved cognitive performance of aged Tg2576 mice.
Moreover, NPT088 reduced phospho-tau pathology, reduced brain atrophy, and improved cognition
in rTg4510 mice.
Discussion: These observations establish NPT088 as a novel therapeutic approach and potential drug
class that targets both Ab and tau, the hallmark pathologies of AD.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Keywords: GAIM; General amyloid interaction motif; Novel object recognition; Spontaneous alternation; Limb clasping;
Thioflavin S; Brain weight; Cerebrospinal fluid; Phospho-tau
1. Background
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder defined by dementia and the presence of
extracellular plaques and intracellular neurofibrillary tangles,
which are comprised of aggregates containing misfolded Ab
and tau, respectively [1,2]. Current therapeutic approaches
for AD target one of these two protein aggregates. Most
clinical trials testing the efficacy of Ab immunization have
not demonstrated significant functional improvements in
patients [3–7]. Moreover, compounds targeting tau
aggregation are still too early in clinical development to
determine whether an approach specifically directed at tau
aggregates will be efficacious [8,9].
Based on the clinical failures using Ab immunization and
animal model studies, it is postulated that therapeutic
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strategies for binding and subsequent clearing of Ab aggre-
gates should ideally exhibit high-affinity binding to aggre-
gated forms of the misfolded proteins (i.e., oligomers,
fibers, or plaques) while sparing monomeric or native spe-
cies [10,11]. In support of this hypothesis, phase I results
from the ongoing PRIME clinical trial of aducanumab, a
monoclonal antibody (mAb) that specifically targets
aggregated Ab, demonstrated significant reduction of Ab
plaque by PET imaging associated with significant
cognitive improvement [12]. Although these results are
promising and suggest that treatment with Ab-directed ther-
apeutics could alter AD progression, the patient population
enrolled was specifically selected to exhibit a mild form of
the disease, and measurements of changes in tau aggregate
loads, which correlate more closely with cognitive function,
were not reported. Here, we propose a therapeutic approach
for AD that broadly targets aggregates of both Ab and tau but
without affecting their respective monomeric forms.
It was previously reported that the filamentous bacterio-
phageM13 (M13) improves cognition and decreases Ab pla-
que loads in APP-overexpressing transgenic mice after
chronic administration [13]. Further research to understand
the mechanism of this anti-amyloid activity revealed that
M13 binds to and remodels multiple types of misfolded pro-
tein aggregates in vitro, including Ab, tau, and a-synuclein,
without binding to monomeric forms of these proteins [14],
and that M13 targeting of misfolded protein aggregates is
mediated by a two-domain fragment of the phage capsid pro-
tein g3p. Therefore, g3p functions as a general amyloid
interaction motif (GAIM), targeting multiple misfolded pro-
teins. A fusion protein, NPT088, was engineered that con-
sists of the active fragment of g3p and human-IgG1-Fc
Fig. 1. Generation and in vitro characterization of NPT088, an immunoglobulin-GAIM fusion protein. (A) Native bacteriophage M13 potently and broadly
binds to and disrupts a variety of misfolded protein assemblies, including Ab, tau, a-synuclein, and yeast prion Sup35. M13, owing to its large size
(17MDa), represents a significant hurdle for effective CNS drug delivery. Subsequent characterization of amyloid fiber binding and remodeling ofM13 revealed
that the minor capsid protein, gene 3 protein (g3p), is critical for this activity and, furthermore, that the two N-terminal domains of g3p facilitate binding and
disruption of amyloids as a general amyloid interactionmotif (GAIM). The engineered fusion protein, NPT088 (NPT088), consists of the active fragment of g3p
and human-IgG1-Fc. (B) Incubation of differentiated N2a cells with 2 mM (9 mg/mL) Ab42 ADDLs for 24-hour-induced robust cytotoxicity. Preincubation of
ADDLs with NPT088 for 3 hours significantly inhibited cytotoxicity. Co-application of ADDL and NPT088 (Time 0 control) had no effect on induction of
cytotoxicity. Asterisks indicate significant difference from ADDL alone (Dunnett’s test, ***P , .001, ****P , .0001). (C) NPT088 was used to precipitate
Ab from formic acid lysates of aged Tg2576 brain. Precipitates were resolved on SDS-PAGE and western blots probed with a monoclonal anti-Ab antibody
(6E10). NPT088 precipitated Ab from formic acid extracts of brain prepared from two different Tg2576 mice (Tg). No Ab was extracted from lysates prepared
fromWTmice. NS indicates nonspecific band that is present in formic acid extracts fromWT brains and is recognized by 6E10. hAPP represents human amyloid
precursor protein. Note the enrichment of all species of Ab in the immunoprecipitated lanes relative to the Input material lane. (D) Transmission electron mi-
croscopy images of Ab42 fiber preparations incubated for 7 days and stained with 1% uranyl acetate. (a–b) Examples of Ab fiber structure after incubation for
7 days in buffer alone. (c–d) Examples of Ab42 fiber structure after incubation with NPT088 (0.25 mM) for 7 days. Note the dramatic loss of fiber structure.
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[14] (Fig. 1A), which has physical properties suitable for
systemic administration. Here, in vivo data are presented
that support the development of NPT088 as a clinical
candidate for the treatment of AD.
2. Methods
2.1. Cytotoxicity assay
ADDL (Ab42-derived diffusible ligands) assembled from
Ab42 peptides was prepared as described in [15]. Briefly,
Ab42 peptide (0.225 mg/mL or 50 mM) was dissolved in
cold F12 medium without phenol red and refrigerated (4–
8C) for 24 hours. The resulting ADDL preparations were
spun at 14,000! g for 15 minutes to remove any fibrillar ma-
terial and then directly used for cytotoxicity assays. SEC anal-
ysis (Superdex 75HR) of this preparation confirmed that Ab42
peptides assemble into oligomeric aggregates that range in
size between 17 kDa and 70 kDa (data not shown).
N2a cells (5000 cells/well) were serum starved for 48
hours to induce differentiation. Cytotoxicity was induced
via incubation with (ADDL, 2 mM or 9 mg/mL) for 24 hours.
Cytotoxicity was assessed by quantifying the amount of the
cytosolic enzyme adenylate kinase released into the media.
Prevention of cytotoxicity was assessed by pre-incubation
of ADDL preparations with NPT088 for 3 hours before
application to cells. Data were analyzed by 1-way ANOVA,
and post-hoc comparisons were made with Dunnett test. P
value was set at .05.
2.2. Ab42 fiber remodeling
Ab42 fiber preparations (2.5 mM)weremade as previously
described [14]. Fiber preparations were incubated for 7 days
with either buffer alone or with NPT088 (0.25 mM). After in-
cubation, Ab42 fiber preparations were stained with 1% ura-
nyl acetate, prepared for electron microscopy, and visualized
with transmission electron microscopy.
2.3. Transgenic mice
Tg2576 [16] mice purchased from Taconic (Model 1349,
mixed C57Bl6/SJL background) and bi-transgenic rTg4510
[17] mice (FVB/N and 129S6 background) were bred in-
house. Mice were maintained on a 12:12 light:dark cycle,
and food (LabDiet, Purina) and water were provided ad libi-
tum. In experiments that involved repeated, weekly dosing
with NPT088, all mice in each treatment group, including
phosphate buffered saline (PBS) control animals, were
immunologically tolerized by an intraperitoneal (IP)
injection of 0.5 mg of monoclonal rat anti-mouse CD4
(eBioscience, Clone GK1.5, #16-0041) 24 hours before the
first dose of NPT088 or PBS. This procedure, which has
been successfully used in other published studies of anti-
amyloid monoclonal antibodies containing Fc-Hu-IgG1
like NPT088 [18], has been shown to deplete CD41 T-cells
resulting in tolerance of foreign antigens [19]. To minimize
variability in pathology and disease progression, all analyses
reported were conducted on male mice. All procedures were
performed in accordance with local and federal guidelines
for the ethical use and treatment of animals and under the su-
pervision of an institutional animal care and use committee.
2.4. Behavioral testing
2.4.1. Spontaneous alternation
Mice were placed into one arm of a Y-maze (Arms:
30 cm L! 10 cm W! 20 cm H) facing the central zone,
and activity was monitored for a period of 10 minutes. Light
levels in the Y-maze were approximately 210 lux. Between
subjects, the arenas were wiped with 70% ethanol (EtOH)
followed by distilled water (dH2O) to reduce olfactory
cues. A successful alternation occurred when a mouse
entered a different arm on three consecutive arm entries.
Locomotor activity and arm entries were quantified by
with TopScan (CleverSys, Reston, VA). Arm entry occurred
when a subject’s center of mass crossed into the beginning
of an arm. Alternation rate was calculated as:
number of alternations=number of arm entries22. Statisti-
cal analysis was performed with 1-way ANOVA and
post-hoc comparisons made with Dunnett test. P value was
set at .05.
2.4.2. Novel object recognition
NOR was performed in an open field arena (50 cm L!
50 cm W ! 40 cm H; w210 lux). Between subjects, the
arenas were wiped with 70% EtOH followed by dH2O.
Testing was conducted over 2 days. Day 1 was a
30-minute arena habituation session where individual mice
were permitted to freely explore the empty arena. Day 2
included both the sample and test phase of NOR. During
the sample phase, mice were placed into the arena and
permitted to freely explore two identical objects for 15 mi-
nutes. Four hours after completion of the sample phase,
mice were placed back into the arena and permitted to freely
explore a familiar and a novel object for 10 minutes. For
each phase of the task, mice were placed in the center of
the arena at the beginning of a session, and the arena and ob-
jects were thoroughly cleaned with 70% EtOH then dH2O at
the end of each session. Objects were placed 5 cm away from
the walls of the arena, and location of objects in the sample
and test phases was identical. All objects were screened in a
separate cohort of mice for differences in exploratory
behavior elicited from mice, and only objects that elicited
comparable levels of exploratory behavior when both were
novel were used in this study. Objects (bowl & jar, approx.
5 cm in each dimension) were counterbalanced across all
groups to further minimize any potential effect of object
on this task. Locomotor activity and object explorations
were quantified with TopScan (CleverSys). An object explo-
ration occurred when the subject’s nose was within 2 cm of
the object, and the midpoint of the subject’s body was
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beyond 2 cm from the object. NOR was assessed using the
discrimination index ([Tnovel 2 Tfamiliar]/Ttotal). Statistical
analysis was performed either with 1-way ANOVA and
post-hoc comparisons performed with Dunnett test when
there were three or more treatment groups, or a t test when
only 2 treatment groups were compared. P value was set at
.05.
2.4.3. Limb clasping
Mice were raised by the tail for 5 seconds over the home
cage and scored for limb clasping on a scale of 0–5.
Zero 5 no limbs clasping, 1 5 one limb clasping,
2 5 two limbs clasping, 3 5 three limbs clasping, 4 5 all
four limbs clasping, 5 5 all limbs clasping severely. Scores
from two independent observers simultaneously observing
the mice were averaged. Statistical analysis was performed
with 1-way ANOVA and post-hoc comparisons made using
Dunnett test. P value was set at .05.
2.5. Tissue collection
Mice were deeply anesthetized with a combination of
dexdomitor (0.3 mg/kg) and telazol (20 mg/kg), transcar-
dially perfused with saline and brains were removed. In
some experiments (Section 3.3.3), brains were weighed on
a digital scale immediately after removal from the skull.
Brains were hemisected, and the right hemibrain was immer-
sion fixed in 4% paraformaldehyde (in PBS, pH 7.4) for
2 days at 4C. After fixation, brains were transferred to a
30% sucrose solution (in PBS, pH 7.4) and cut in the coronal
or sagittal plane at 40 mm on a freezing sliding microtome.
The left hemisphere was immediately microdissected on
wet ice, and frontal brain, caudal brain, hippocampus, cere-
bellum, and olfactory bulb were frozen in separate tubes in
liquid nitrogen.
2.6. CSF collection
In some mice, cerebrospinal fluid (CSF) was collected
before obtaining brain tissue. After administration of anes-
thesia (see Section 2.5), each mouse was positioned such
that CSF flowed backward. A small incision in the skin
and muscles permitted puncture of the cisterna magna mem-
brane with the tip of a 30G needle. A gel-loading pipette tip
covered the puncture hole to create a seal and suction was
applied to draw CSF (6–12 mL). CSF was centrifuged at
5000! g for 10 minutes at 4C and the resulting supernatant
aliquoted for analysis of Ab1–xx (see Section 2.9).
2.7. Immunoprecipitation of Ab by NPT088 in brain tissue
2.7.1. Tissue homogenization and fractionation
Frozen cortices from aged Tg2576mice (20 mo) were ho-
mogenized and processed [20]. After a tris-buffered saline
(TBS) and Triton-X extraction, insoluble Ab was collected
by extraction with 70% formic acid (FA) followed by
sonication with a bath sonicator. FA extraction was restricted
to 3 hours to ensure that samples contained substantial
amounts of higher molecular weight aggregates. After
centrifugation (175,000! g for 30 minutes at 4C), the su-
pernatant was collected and frozen at 280C. Before use,
the FA fraction was neutralized with 1M Tris base (1:27
v:v). The FA-soluble fraction used in the immunoprecipita-
tion experiments is referred to as the “Insoluble” fraction.
2.7.2. Immunoprecipitation
The insoluble fraction was incubated with protein A/G
sepharose beads (GE Healthcare, cat # 17-0618-01; 17-
0780-01) for 60 minutes at 4C. After centrifugation
(3500! g for 2 minutes at 4C), the supernatant was
collected and diluted 1:1 in PBS buffer with 20% Superblock
(ThermoFisher, cat # 37,515) and 0.1% Tween. NPT088-
coupled Dynabeads (Invitrogen, cat # 2017-08) were incu-
bated with the insoluble fraction for 1.5 hours at 37C. Beads
were washed in 300-mM NaCl phosphate buffer with 0.05%
Tween followed by washes in 137-mM NaCl phosphate
buffer10.05% Tween. Beads were incubated in 1! lithium
dodecyl sulfate reducing sample buffer (LDS, Thermo-
Fisher, cat# NP0007) for 10 minutes at 95C, and bound
proteins were separated on NuPAGE 4%–12% Bis-Tris
gels (Life Technologies, cat: WG1401BX10). After transfer
to nitrocellulose membrane, the membrane was boiled in
PBS for 2min and blocked in 5%milk in TBS–0.05%Tween
for 1 hour at room temperature (RT). Ab was detected with
6E10 (Covance, cat#: 39,320), which recognizes both APP
and Ab [see 21], in 5% milk in TBS–0.05% Tween for
18 hours at 4C.
2.8. Quantification of Ab42 in brain tissue
2.8.1. Tissue homogenization and fractionation
Frozen frontal brain (rostral from Bregma) and hippo-
campus was homogenized and processed as previously
described [22]. Briefly, tissue was thawed on ice, weighed,
and homogenized at a concentration of 1 mL/150 mg, with
buffer consisting of 10-mL RIPA (Sigma, cat #R0278),
1 Complete ULTA tablet (Roche 05-892-970-001), 1 phos-
STOP tablet (Roche 04-906-845), and 0.5-mL 5M EDTA.
Brains were sonicated on ice (Fisher Scientific model
FB705 ultra tip sonicator, 10 seconds) and spun at
100,000! g for 30 minutes at 4C. The supernatant (S1)
was collected, aliquoted, and frozen at 280C until further
use. The remaining pellet was homogenized in 70% formic
acid (FA) to a concentration of 2 mL/mg tissue. The pellet
was sonicated on ice, as above, and spun at 100,000! g
for 30 minutes at 4C. The supernatant (S2) was collected,
aliquoted, and frozen at 280C. Just before use, S2 was
neutralized with 1M Tris base (1:20 v:v). In this study,
S1 is referred to as the “Soluble” fraction and S2 as the
“insoluble” fraction.
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2.8.2. Ab42 ELISA
Levels of Ab1–42 (Ab42) were measured using the Innot-
est b-amyloid(1–42) test kit (FujiRebio, Malvern, PA, cat #:
80,177, lot #: 232810). The investigator performing the anal-
ysis was blind to treatment groups. Samples were run
according to kit instructions. After adjustment for log-
transformation and dilution, the unknown values were
normalized to protein concentration, obtained from the
same sample aliquot using a BCA assay (ThermoFisher,
Carlsbad, CA, cat # 23,252), to derive final Ab42 values in
pmol/g. Values were excluded if they were either below
the lower limit of quantification (LLOQ; ,0.04 pmol/g
and 0.09 pmol/g, for soluble and insoluble fractions, respec-
tively) or if agreement among dilution values was ,70%.
Statistical analysis was performed with 1-way ANOVA
and post hoc comparisons made with Dunnett test. P value
was set at .05.
2.9. Quantification of Ab1–38, Ab1–40, and Ab1–42 in CSF
CSF levels of total human Ab1–42, Ab1–40, and Ab1–38
were measured using MesoScale Discovery Ab Peptide
Panel 1 (6E10) VPLEX kit (cat #K15200E). Samples were
run according to manufacturer’s instructions. Unknown
values are reported as pg Ab/mL CSF. Statistical analysis
was performed with 1-way ANOVA, and post hoc compari-
sons were made with Dunnett test. P value was set at .05.
2.10. Neuropathology
2.10.1. Tissue sectioning and processing
Right hemibrains were sectioned coronally at 40 mm, or
sagittally at 30 mm, on a freezing sliding microtome and
stored in a glycerol-based cryoprotectant at 220C before
immunostaining of Ab1–x (82E1) and p-tau (AT8).
Sectioning and staining were performed either at NeuroSci-
ence Associates (NSA, Knoxville, TN) using their
MultiBrain Technology and in-house staining procedures
(https://www.neuroscienceassociates.com/technologies/
multibrain/) or in the laboratory of E. Mufson at Rush Uni-
versity Medical Center (Chicago, IL).
In the Mufson laboratory, immunostaining was per-
formed at RT on floating sections that were incubated over-
night in primary antibodies (biotinylated 82E1, IBL cat #
10,326, 1:2000; AT8, ThermoFisher cat # MN1020,
1:3000; biotinylated AT8, ThermoFisher cat # MN1020B,
1:3000). For non-biotinylated primary antibodies, sections
were incubated in biotinylated secondary antibodies directed
against the appropriate species IgG. Detection of bio-
tinylated reagents was performed with the Vectastain Elite
ABC Kit (Vector Laboratories cat #: PK-6100) for 60
minutes and the DAB Peroxidase Substrate Kit (Vector
Laboratories cat #: SK-4100) according to the manufac-
turer’s instructions.
Fibrillary Ab was visualized using thioflavin S (thioS)
histochemistry, and cytoarchitectonics were visualized
with thionine staining performed by NSA.
2.10.2. Imaging and analysis
Neuropathologic analyses of all immunohistochemical
labeling were performed on 12-bit monochrome images of
the dorsal hippocampus or overlying cortex in 2–3 sec-
tions/brain at 240 mm (coronal) or 180 mm (sagittal) inter-
vals. The lowest magnification at which measurements
were not significantly different from higher magnifications
was chosen for image capture. Magnification was selected
based on measurements in the same area in a section at
different magnifications in five mice. Sections were at com-
parable rostro-caudal or medial-lateral levels between
brains, and all images were captured at the same exposure
time. MetaMorph software was used for image analyses.
Total area of 82E1 immunostaining (very diffuse Ab
excluded) within the regions of interest (ROIs; entire dorsal
hippocampus area and overlying cortical area) and AT8 im-
munostaining in the entire dorsal hippocampus area was
quantified in thresholded images (magnification of 4!)
and expressed as a percentage of the ROI area. Quantifica-
tion of the fluorescent signal of thioS was performed simi-
larly in Tg2576 mice, and the number of thioS-positive
plaques was also counted. ThioS in sagittal images (magni-
fication of 10!) of the cortex of rTg2576 mice was quanti-
fied as a percentage of a ROI approximately 0.19 mm2, one
designed to fit within all the variations in brain size seen in
this model for tau pathology. The thickness of the CA1 py-
ramidal cell layer was measured at four evenly spaced points
in the region between the CA1/CA2 boundary and the apex
of CA1 in each section using ImageJ software and these four
values were averaged for each brain. Data were analyzed
with a 1-way ANOVA and post hoc comparisons made
with Dunnett test. P value was set at .05.
3. Results
3.1. Characterization of NPT088 in vitro
NPT088 is a novel immunoglobulin fusion protein that is
bivalent for GAIM (Fig. 1A). We previously demonstrated
in vitro that both M13 and NPT088 efficiently bind to Ab fi-
bers, and that neither M13 nor NPT088 exhibit binding to
Ab monomers [14]. Although fibrillar species of Ab are
prevalent in plaques, cognitive impairment [23,24] and
disruption of synaptic plasticity [24,25] are associated with
lower molecular weight toxic oligomers of Ab. To
determine whether NPT088 could inhibit cytotoxicity
induced by Ab oligomers, we investigated whether
pretreatment of Ab42 ADDLs with NPT088-inhibited cyto-
toxicity induced in differentiated N2a cells. Exposure of
differentiated N2a cells to ADDLs (2 mM, 9 mg/mL) for
24-hour–induced robust cytotoxicity (Fig. 1B). Pretreatment
of ADDLs with NPT088 for 3 hours significantly inhibited
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cytotoxicity (Fig. 1B, Dunnett’s post-hoc: 46 nM vs. ADDL,
P , .0001; 4.6 nM vs. ADDL, P , .0001, 0.46 nM vs.
ADDL, P5 .0009). When ADDLs and NPT088 were added
to cultures simultaneously, no effect was observed on cyto-
toxicity (Fig. 1B, Dunnett’s post-hoc: 0.46 nM [Time 0]
vs. ADDL, P5 .4) indicating that effect of NPT088 on cyto-
toxicity was due to binding to ADDLs and not a nonspecific
interaction with N2a cells. Moreover, the IC50 values of
NPT088 calculated in these assays are 5–50 nM, suggesting
that NPT088 binds Ab and neutralizes toxicity at sub-
stoichiometric ratios (1 NPT088: 40-400 Ab42 monomers),
consistent with the hypothesis that the NPT088-mediated in-
hibition of cytotoxicity was due to interaction with oligo-
meric species of Ab.
To further demonstrate NPT088 binding to Ab, a formic
acid–soluble (FA) fraction of Tg2576 brain lysates was
used to assess the ability of NPT088 to immunoprecipitate
Ab. The Ab in the FA fraction is a heterogeneous mix of
monomeric Ab and non-denatured larger amyloid aggregates
(Supplementary Fig. 1). NPT088 successfully immunopre-
cipitated various species of Ab from the FA fraction of
Tg2576 brain lysates (Fig. 1C). Although the conformation
of NPT088-interacting species in the FA fraction is not
known, NPT088 does not bind to Ab monomers in vitro
and likely interacts with aggregated Ab species consisting
of SDS-stable Ab dimers and higher order Ab-mers
(Fig. 1C). The hAPP observed in these lysates is associated
with high molecular weight, aggregated Ab
(Supplementary Fig. 1) and is consistent with previous
studies demonstrating inclusion of misfolded hAPP in
growing intracellular amyloid aggregates [26]. To test for ef-
fects of NPT088 on amyloid fibers, Ab42 fibers were incu-
bated with NPT088 (0.25 mM) for 7 days, and this resulted
in remodeling of fibrillar Ab into amorphous deposits
(Fig. 1D, see also Supplementary Fig. 2A and 2B). In addi-
tion, NPT088 remodels fibers assembled from the microtu-
bule binding region of tau (Supplementary Fig. 2C), which
is notable as these fibers are transmission-competent after
sonication (Supplementary Fig. 3). All the remodeling data
presented in the present study are consistent with previous re-
modeling assays of GAIM-based molecules [14]. Collec-
tively, the in vitro characterization of NPT088 indicates
that it effectively targets several species of aggregated Ab,
suggesting that it could mediate reduction of Ab pathology
in vivo.
3.2. NPT088 in Tg2576 mice
3.2.1. Brain exposure of NPT088
To confirm that NPT088 was able to enter the central ner-
vous system (CNS) when administered via IP injection,
NPT088 was quantified in homogenates of frontal cortex
from aged (19–20 mo) male Tg2576 mice after a single, IP
injection (10 mg/kg). Levels of NPT088 were maximal 1
day after injection (4.7 ng/mg; Supplementary Fig. 4).
NPT088 was still detectable 14 days after injection
(Supplementary Fig. 4). These results confirm that
NPT088 is able to enter the CNS of aged Tg2576 mice after
IP injection.
3.2.2. Improvement in cognitive function
NPT088 was engineered to contain an IgG1-Fc (Fig. 1A),
which provides antibody-like pharmacokinetic, tissue distri-
bution, and effector function properties. To assess whether
systemically administered NPT088 affected the cognitive
function, performance in the spontaneous alternation and
NOR tasks was measured. Previous studies have shown
that aged Tg2576 mice exhibit significant deficits in sponta-
neous alternation and NOR [16,27,28]. After administration
of 10 doses of NPT088 to Tg2576mice (16–19 months at the
beginning of the experiment, 18–21 months at time of
testing), spontaneous alternation in the Y-maze was
measured during week 10 (Fig. 2A). A significant increase
in the spontaneous alternation rate was observed in the high-
est dose (20 mg/kg) group (Dunnett’s post-hoc, 20 mg/kg vs.
PBS, P, .05). After administration of a further four doses of
NPT088, NOR was assessed during week 14 (19–22 months
at time of testing; Fig. 2B). Similar to spontaneous alterna-
tion in the Y-maze, a significant increase in novel object
recognition was observed at the highest (20 mg/kg) dose
(Dunnett’s post-hoc, 20 mg/kg vs. PBS, P , .05).
3.2.3. Reduction of soluble & insoluble Ab42
The improvements in cognitive performance were
accompanied by a significant reduction of soluble and insol-
uble Ab42 in both the hippocampus (Soluble: Fig. 2C, Dun-
nett’s post-hoc, 0.2 mg/kg vs. PBS, P , .01; 2 mg/kg vs.
PBS, P , .01; 20 mg/kg vs. PBS, P , .05; Insoluble:
Fig. 2D, Dunnett’s post-hoc, 2 mg/kg vs. PBS, P , .05)
and frontal cortex (Soluble: Fig. 2E, Dunnett’s post-hoc,
0.2 mg/kg vs. PBS, P , .01; 2 mg/kg vs. PBS, P , .01;
20 mg/kg vs. PBS, P , .05; Insoluble: Fig. 2F, Dunnett’s
post-hoc, 2 mg/kg vs. PBS, P , .01; 20 mg/kg vs. PBS,
P , .05). Reductions in soluble and insoluble species of
Ab42 are consistent with the ability of NPT088 to interact
with both soluble (Fig. 1B and 1C) and insoluble fibrillar
species of Ab (Fig. 1D, Supplementary Fig. 2A and 2B).
These results indicate that NPT088, when administered sys-
temically, was able to mitigate cognitive impairments in
aged Tg2576 mice, potentially through removal of soluble
and insoluble species of Ab42.
3.2.4. Reduction of Ab neuropathology
To confirm NPT088 can engage Ab and mediate its clear-
ance from the brain, tissue sections from the
paraformaldehyde-fixed hemisphere of aged Tg2576 mice
were immunostained for Ab. Mice treated with NPT088
demonstrated significantly less Ab immunostaining in the
hippocampus relative to mice treated with PBS (Fig. 3A
and 3B; Fisher post hoc, 0.2 mg/kg vs. PBS, P , .05;
2 mg/kg vs. PBS, P , .05; 20 mg/kg vs. PBS, P , .05).
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Similar to observations made in the hippocampus, signifi-
cant reductions of cortical Ab immunostaining were
observed in all treatment groups (Fig. 3C and 3D; Fisher
post hoc, 0.2 mg/kg vs. PBS, P , .01; 2 mg/kg vs. PBS,
P , .001; 20 mg/kg vs. PBS, P , .05). Analysis of cortical
thioS histochemical staining revealed significant decreases
in the number of thioS-reactive plaques only in the 2 and
20 mg/kg but not the 0.2 mg/kg treatment groups (Fig. 3E
and 3F; Fisher’s post hoc, 2 mg/kg vs. PBS, P , .05;
20 mg/kg vs. PBS, P , .05). Reduction of Ab plaque was
not associated with an increase in microhemorrhage
(Supplementary Fig. 5) as detected using Perls iron staining.
3.2.5. Reduction in levels of Ab1-xx in CSF
To determine whether NPT088 facilitated movement of
Ab from parenchyma into adjacent fluid compartments,
Fig. 2. Systemically administered NPT088 improves cognition in aged Tg2576 mice. Behavior was assessed in aged Tg2576mice (16–19 months at the start of
dosing) after repeated, weekly IP administration of NPT088. (A) Spontaneous alternation in a Y-maze was significantly increased after 10 weeks of weekly
dosing with NPT088 at 20 mg/kg (q475 2.8, P5 .01). N5 13 (PBS), 13 (0.2 mg/kg), 12 (2 mg/kg), 13 (20 mg/kg). (B) Performance of novel object recognition
was significantly increased after 14 weeks of weekly dosing with NPT088 at 20 mg/kg (q40 5 2.1, P 5 .05). N5 11 (PBS), 11 (0.2 mg/kg), 12 (2 mg/kg), 10
(20 mg/kg). (C) Systemic NPT088 significantly reduced levels of Ab42 from the soluble fraction of hippocampus at all doses tested (0.2 mg/kg: q44 5 3.6,
P 5 .003; 2 mg/kg: q44 5 3.3, P 5 .005; 20 mg/kg: q44 5 2.4, P 5 .05). N 5 12 (PBS), 11 (0.2 mg/kg), 12 (2 mg/kg), 13 (20 mg/kg). (D) Systemic
NPT088 significantly reduced levels of Ab42 from the insoluble fraction of hippocampus when administered at 2 mg/kg (q46 5 2.7, P 5 .02). N 5 13
(PBS), 12 (0.2 mg/kg), 12 (2 mg/kg), 13 (20 mg/kg). (E) Systemic NPT088 significantly reduced levels of Ab42 from the soluble fraction of cortex at all doses
tested (0.2mg/kg: q475 3.1,P5 .01; 2 mg/kg: q475 3.1,P5 .01; 20mg/kg: q475 2.4,P5 .05). N5 13 (PBS), 13 (0.2 mg/kg), 13 (2mg/kg), 12 (20mg/kg). (F)
Systemic NPT088 significantly reduced levels of Ab42 in the insoluble fraction of cortex at 2 and 20 mg/kg (2 mg/kg: q475 3.6, P5 .002; 20 mg/kg: q475 2.1,
P 5 .05). N 5 13 (PBS), 12 (0.2 mg/kg), 13 (2 mg/kg), 13 (20 mg/kg). In all panels, asterisks indicate significant difference versus Tg-PBS.
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CSF was collected from aged Tg2576 mice (20–21 months
at study start) after 13 weeks of weekly IP dosing with
NPT088. CSF was also collected from a separate group
of mice before initiation of dosing to gain insight into
baseline levels of Ab. Weekly dosing with NPT088 was
associated with significantly less Ab1–38 (Fig. 4A; Dun-
nett’s post hoc, Tg-NPT088 vs. Tg-PBS, P , .05) and
Ab1–40 (Fig. 4B; Dunnett’s post hoc, Tg-NPT088 vs. Tg-
PBS, P , .05) compared to PBS-treated Tg2576 mice.
Dosing with NPT088 did not significantly affect CSF
levels of Ab1–42 (Fig. 4C; Dunnett’s post hoc, Tg-
NPT088 vs. Tg-PBS, P 5 .15). Levels of Ab1–40 and
Ab1–42 observed here were consistent with previously
published observations in aged Tg2576 mice [29]. Collec-
tively, these results indicate that NPT088 does not shunt
soluble species of Ab into nonparenchymal fluidic com-
partments suggesting that NPT088-mediated reductions
in Ab occur by direct remodeling of insoluble species
Fig. 3. Systemically administered NPT088 reduces Ab plaque and Ab42 in aged Tg2576 mice. Aged Tg2576 mice (16–19 months at the start of dosing)
received 14 weeks of weekly, IP injections of NPT088 at ascending doses (0.2, 2, 20 mg/kg). Tissue was harvested 24 hours after the last injection. (A) Repre-
sentative images of 82E1-immunostained Ab in the hippocampus showing reduction after treatment with NPT088. Scale bars5 500 mm. (B) Summary quan-
tification of 82E1 immunostaining from three coronal sections at 240-mm intervals indicating significant reduction of total Ab plaque in the hippocampus at all
doses tested. N5 11 (PBS), 10 (0.2 mg/kg), 12 (2 mg/kg), 10 (20 mg/kg). Asterisks indicate significant difference versus Tg-PBS. (C) Representative images of
82E1 immunostaining in the cortex showing reduction of Ab after treatment with NPT088. Scale bars5 500 mm. (D) Summary quantification of 82E1 immu-
nostaining from three sections indicating significant reduction of Ab in the hippocampus at all doses tested. N 5 11 (PBS), 10 (0.2 mg/kg), 11 (2 mg/kg), 9
(20 mg/kg). Asterisks indicate significant difference vs. Tg-PBS. (E) Representative images of thioflavin-S staining in the cortex showing reduction in the num-
ber of fibrillar Ab plaques after treatment with NPT088. Scale bars5 500 mm. (F) Summary quantification from two sections of thioflavin-S staining indicating
significant reduction of fibrillar Ab plaque number in the hippocampus at 2 and 20 mg/kg (2 mg/kg: t415 1.9, P5 .04; 20 mg/kg: t415 2.0, P5 .03). N5 10
(PBS), 11 (0.2 mg/kg), 13 (2 mg/kg), 11 (20 mg/kg). Asterisks indicate significant difference versus Tg-PBS.
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and/or clearance of soluble and/or insoluble species via
cellular mechanisms (i.e., phagocytosis).
3.3. NPT088 in rTg4510 mice
3.3.1. Improvement in cognitive and motor function
A unique feature of NPT088 is its ability to bind to and
remodel amyloid aggregates independent of primary
sequence, including aggregates of tau [14]. To determine
whether NPT088 was able to affect tau neuropathology
in vivo, we dosed the rTg4510 tauopathy mouse model
[17] with NPT088 (20 mg/kg) or PBS weekly (IP) for
14 weeks (3.5 months at beginning of experiment). Previous
studies indicate that rTg4510 mice exhibit significant defi-
cits in the novel object recognition [30]. Performance of
PBS-treated rTg4510 mice (6.3 months at the time of
testing) in the NOR task tended to be lower than WT litter-
mate mice (Fig. 5A; Fisher post hoc, WT vs. Tg-PBS,
P , .1). After 14 weeks of NPT088 treatment, a significant
improvement in performance of the NOR task was observed
in rTg4510 mice (Fig. 5A; Fisher post hoc, Tg-PBS vs.
Tg-NPT088, P , .05). Importantly, performance in the test
was not correlated with spontaneous locomotor behavior
(Supplementary Fig. 6), indicating that the changes in cogni-
tive performance were not due to changes in motor behavior.
In addition to cognitive impairments, rTg4510 mice
exhibit atrophy of dorsal corticospinal tracts leading to
limb clasping and other functional motor deficits [31,32].
Such a clasping phenotype has been observed in several
tau transgenic mouse models at young ages including
P301S mice at age of 3 months [33], line 44 mice at age of
5 months [34], and Tau-4R/2N mice at age of 6–8 weeks
[35]. To determine whether NPT088 altered functional mo-
tor performance of rTg4510 mice, we assessed limb clasping
at the age of 5–6 months after 14 weeks of weekly dosing
with NPT088. As expected, PBS-treated rTg4510 mice ex-
hibited significantly more limb clasping when suspended
by the tail relative to WT littermates (Fig. 5B; Dunnett’s
post hoc, P , .05). Treatment with NPT088 significantly
ameliorated limb clasping abnormalities in rTg4510 mice
(Fig. 5B; Dunnett’s post hoc, P , .05).
3.3.2. Reduction in p-tau and fibrillar tau
To determinewhether treatment with NPT088 was able to
reduce levels of p-tau immunostaining and fibrillar tau spe-
cies in brain regions relevant to cognition, AT8 (pSer202/
pThr205) p-tau and thioS staining were quantified. A signif-
icant decrease in AT8 p-tau immunostaining of the somato-
dendritic compartment in hippocampal pyramidal cells was
observed after NPT088 treatment (Fig. 5C; Mann–Whitney
test, P, .05). Moreover, significant decreases in thioS stain-
ing of cortical neurons were observed in tissue from mice
treated with NPT088 compared to PBS-treated mice
(Fig. 5D; Mann–Whitney test, P, .05). Additionally, frozen
cortex from the contralateral hemisphere was analyzed bio-
chemically viaWestern blot using AT8, pSer422, and AT270
antibodies. Significant reductions of AT8 were observed in a
high-salt insoluble-pellet enriched for neurofibrillary tangles
(Supplementary Fig. 7A; t test, P , .05). In a Triton-X sol-
uble fraction, levels of pSer422 were significantly reduced
(Supplementary Fig. 7B; t test, P , .05), and a trend was
observed for reduction of AT270 (Supplementary Fig. 7C;
t test, P , .08). The reductions in levels of AT8, pSer422,
and AT270 were replicated in a separate cohort of mice
(AT8: Supplementary Fig. 7D; pSer422: Supplementary
Fig. 7E; AT270: Supplementary Fig. 7F).
3.3.3. Aged rTg4510: reduction in brain atrophy and
fibrillar tau and cognitive improvement
A hallmark of the rTg4510 tauopathy mouse model is se-
vere forebrain neurodegeneration, which is significant in
mice aged .5 months [31]. To assess whether NPT088
could affect the amount of neurodegeneration exhibited by
this mouse, rTg4510 mice (5.7 months at study start)
received 13 weekly IP doses of NPT088 (2 mg/kg). Brains
Fig. 4. Systemically administered NPT088 reduces Ab in CSF of aged Tg2576 mice. CSF was collected from aged Tg2576 mice (20–21 months at experiment
start) before dosing or after administration of 13 weeks of weekly, IP injections of NPT088 (2 mg/kg). (A) The concentration of Ab1–38 significantly increased in
CSF from aged Tg2576 mice over 13 weeks (q54 5 2.3, P 5 .05). Weekly IP dosing with NPT088 significantly reduced Ab1238 in CSF (q54 5 2.4, P 5 .04).
N 5 19 (Tg-Time 0), N 5 21 (Tg-PBS), N 5 17 (Tg-NPT088). (B) The concentration of Ab1–40 significantly increased in CSF from aged Tg2576 mice over
13 weeks (q53 5 2.5, P 5 .03). Weekly IP dosing with NPT088 significantly reduced Ab1–40 in CSF (q53 5 2.4, P 5 .04). N 5 19 (Tg-Time 0), 20 (Tg-PBS),
N5 17 (Tg-NPT088). One significant outlier (Grubb test) in the Tg-PBS group (77.7 ng/mL) was excluded fromAb1–40 analysis. (C) The concentration of Ab1–
42 did not significantly change in CSF from aged Tg2576mice over 13 weeks of dosing (q525 1.1, P5 .4). Weekly IP dosing with NPT088 did not affect Ab1–42
in CSF (q525 1.8, P5 .15). N5 19 (Tg-Time 0), 20 (Tg-PBS), N5 17 (Tg-NPT088). One significant outlier (Grubb test) in the Tg-PBS group (6.2 ng/mL) was
excluded from Ab1–42 analysis. Asterisks indicate significant difference versus Tg-PBS.
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from rTg4510 mice receiving NPT088 (8.8 months at study
end) weighed significantly more than brains from mice that
received vehicle (Fig. 6A and 6B; t Test, NPT088 vs. PBS,
P , .05). The original characterization of rTg4510 mice
indicated that neurodegeneration was especially robust in
the hippocampus [31]. Thionine-stained sections of hippo-
campus from rTg4510 mice revealed dramatic atrophy of
the hippocampus in mice dosed with PBS that was almost
entirely prevented in mice that received NPT088 (Fig. 6C).
Hippocampal weight of rTg4510 mice dosed with NPT088
was significantly greater than PBS-treated rTg4510 mice
and nearly equivalent to hippocampus weights from
rTg4510 mice at the beginning of the study (Fig. 6D;
Dunnett’s post-hoc, Tg-NPT088 vs. Tg-PBS, P , .05; Tg-
Time 0 vs. Tg-PBS, P , .01). Thickness of stratum pyrami-
dale in area CA1 from rTg4510 mice dosed with NPT088
was significantly greater than that of PBS-treated rTg4510
mice (Fig. 6E; Dunnett’s post hoc, Tg-NPT088 vs.
Tg-PBS, P , .05). A significant reduction in thioS staining
in the cortex was observed (Fig. 6F; Dunnett’s post hoc,
Fig. 5. Systemically administered NPT088 improves cognitive and motor phenotypes and reverses tau pathology in rTg4510 mice. Behavior and levels of p-tau
were assessed in rTg4510mice (3.5mo) that received 14weeks of weekly IP treatment with NPT088 (20mg/kg) or PBS. (A) rTg4510mice treated with NPT088
exhibited significantly better performance in the novel object recognition task relative to rTg4510 mice receiving PBS (t 5 2.3, df 5 7, P 5 .02). N 5 4
(WT-PBS), 4 (Tg-PBS), 5 (Tg-NPT088). Asterisk indicates significant difference versus rTg4510-PBS. (B) rTg4510 mice exhibited significant limb clasping
relative to WT mice when suspended by the tail (q95 2.8, P5 .02). Treatment with NPT088 significantly reversed limb splay abnormality (q95 2.8, P5 .02).
N5 4 (WT-PBS), 4 (Tg-PBS), 5 (Tg-NPT088). (C) Treatment with NPT088 significantly decreased somatodendritic AT8 (pSer202/pThr205) immunostaining
of aggregated p-tau in pyramidal cells of the hippocampus (U5,5 5 3, P 5 .03). Representative images of AT8 immunostaining shown to the left of summary
quantification. AT8 immunostaining was quantified in three sections at 240-mm intervals per animal. Scale bars5 100 mm.N5 5 (Tg-PBS), 5 (Tg-NPT088). (D)
Treatment with NPT088 significantly decreased levels of neuronal thioS in cortex frommice treated with NPT088 (U3,55 0, P5 .02). Representative images of
thioS staining shown to the left of summary quantification. ThioS levels were quantified from three sections per animal. Scale bars5 100 mm.N5 3 (Tg-PBS), 5
(Tg-NPT088). In all panels, asterisk indicates significant difference from Tg-PBS.
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Fig. 6. Systemically administered NPT088 reduced neurodegeneration in rTg4510 mice. rTg4510 mice in this experiment (5.7 mo at start) received 13 weekly
IP doses of NPT088 (2 mg/kg) or PBS. Tissue from a group of 13 rTg4510mice (5.7 mo) was harvested at the beginning of the study to serve as a Time 0 control,
and tissue from group of 3 WT mice (8.8 months) was harvested at the end of the study. (A) Representative images of brains fromWT mice and rTg4510 mice
that received either NPT088 or PBS. Scale bar indicates 5 mm. (B)Wet weight of brains, measured at harvest, from rTg4510mice receiving NPT088 was signif-
icantlymore than brain weights measured from rTg4510mice receiving PBS (t5 1.7, df5 30,P5 .049). Brain weightsmeasured fromWTmice (N5 3) shown
for comparative purposes. N5 3 (WT), 19 (Tg-PBS), 18 (Tg-NPT088). (C) Representative Nissl-stained sagittal sections of hippocampus from rTg4510 mice
harvested at the beginning of the study (Time 0), rTg4510 mice dosed with either PBS (Tg-PBS) or NPT088 (Tg-NPT088), or littermate non-Tg mice (WT).
Scale bars are 200 mm. (D) Weight of left hippocampus of rTg4510 mice treated with NPT088 (8.8 mo at harvest) was significantly greater than the weights
measured from rTg4510 mice dosed with PBS (q475 2.3, P5 .046). Hippocampus weight measured from rTg4510mice harvested at the beginning of the study
(5.7 mo) was also significantly greater than weights from rTg4510 mice dosed with PBS (q475 3.3, P5 .004). Weight of hippocampus from non-Tg littermate
mice (WT) is shown for comparison. N 5 3 (WT), 19 (Tg-PBS), 18 (Tg-NPT088), 13 (Tg-Time 0). (E) Thickness of stratum pyramidale in area CA1 of hip-
pocampuswas significantly greater in rTg4510mice dosed with NPT088 relative to rTg4510mice that received PBS (q405 2.8,P5 .02). Stratum pyramidale of
area CA1 from tissue harvested at the beginning of the study exhibited a trend for increased thickness relative to mice that were dosed with PBS (q40 5 1.8,
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Tg-NPT088 vs. Tg-PBS, P , .05; Tg-Time 0 vs. Tg-PBS,
P , .0001). Moreover, treatment with NPT088 was associ-
ated with functional improvements. After just 4 weeks of
dosing (6.7 months at time of test), rTg4510 mice receiving
NPT088 exhibited a trend for less severe limb clasping rela-
tive to mice dosed with PBS (Fig. 6G; Dunnett’s post hoc,
Tg-NPT088 vs. Tg-PBS, P 5 .13; Tg-Time 0 vs. Tg-PBS,
P , .05). Moreover, at the end of the study (8.7 months at
time of test), mice treated with NPT088 exhibited signifi-
cantly better performance in the novel object recognition
test (Fig. 6H; t Test, P , .05). Collectively, these results
are consistent with NPT088 mitigating the neurodegenera-
tion that occurs in rTg4510 mice, which results in subse-
quent improvements in functional motor and cognitive tests.
4. Discussion
Translation of preclinical therapeutic strategies to suc-
cessful clinical outcomes is particularly challenging for
AD, at least in part because of multiple pathologies and no
apparent single-disease mechanism. Most reported thera-
peutic strategies focused on a single pathologic target such
as Ab [36–38], and the initial wave of Ab-directed
immunotherapies targeted monomeric Ab with
unimpressive efficacy [4–7]. One potential explanation for
the failure of such candidates is sequestration of the
compound by relatively high concentrations of Ab
monomers from the pathologic oligomeric and fibrillar
species, including plaques [10]. In support of this hypothe-
sis, monoclonal antibodies with significant binding to mono-
meric Ab produce little or no efficacy when administered to
preclinical AD models with pre-existing Ab deposits
[39,40], but efficacy was improved in preclinical models
when Ab production was suppressed with co-
administration of a BACE1 inhibitor [41].
NPT088 does not bind monomeric Ab in vitro [14], binds
soluble aggregates of Ab produced in vitro (Fig. 1B) and
derived from Tg2576 mouse brain extracts (Fig. 1C), and
prevents cytotoxicity induced by ADDLs (Fig. 1B).
In vitro, NPT088 binds and remodels fibrillar forms of Ab
in a concentration dependent manner [14] (Fig. 1D,
Supplementary Fig. 2A and 2B). Structural studies of
GAIM suggest that the binding domains associate with
both templating strands of Ab fiber required for fiber growth
[14]. Surface plasmon resonance binding studies show that a
GAIM-fusion is likely to bind a larger surface area (3-to-5-
fold more monomers per fiber) [14] as compared to
antibodies [42]. The activities of NPT088 on Ab in vitro
translate in vivo to robust reductions of soluble and insoluble
forms of Ab (Fig. 2C–2F), including dense core plaques
(Fig. 3A–3D) and fibrillar aggregates (Fig. 3E and 3F)
when NPT088 is administered to Tg2576 mice. Although
these results do not rule out the possibility that NPT088
binds monomers in vivo, they do suggest that the relative
binding affinity of NPT088 on oligomeric and fibrillar Ab
is greater than to monomeric Ab.
The mechanism of NPT088-mediated lowering of Ab-
associated pathology remains unclear. In vitro, NPT088
appears to remodel Ab aggregates into amorphous forms
(Fig. 1D, Supplementary Fig. 2A and 2B). Therefore, clear-
ance of large brain aggregates (i.e., plaques) could be medi-
ated by the inherent remodeling activity of NPT088,
followed by cell-mediated clearance. For example, as
described for other Ab-directed monoclonal antibodies,
NPT088, which contains a human-IgG1-Fc, could engage
microglia to facilitate phagocytosis of NPT088-protein
aggregate complexes [18]. Although we found no evidence
for an increase in the area of microglia staining (Iba1) after
10 or 14 weeks of weekly NPT088 (data not shown), this
observation is not inconsistent with other studies on the
role of activated microglia in clearance of Ab, because
immunoglobulin Fc-mediated microglia activation is tran-
sient after passive immunization [43]. Therefore, we do
not rule out Fc-receptor-mediated microglial activation
by NPT088 and subsequent phagocytosis as a potential
mechanism for NPT088-mediated Ab clearance. Another
potential mechanism for parenchymal clearance of Ab is
via sequestration of Ab to peripheral fluidic compartments.
This mechanism, also known as peripheral sink, is primar-
ily associated with monomer-directed antibodies that facil-
itate the movement of Ab from the parenchyma and into
CSF and blood [44]. We observed no increases in CSF Ab
levels after NPT088 treatment (Fig. 4). Given the concor-
dance between relative changes in levels of Ab in CSF
and blood [29], especially after treatment with Ab-directed
immunotherapies [45–47], the lack of effect of NPT088 on
CSFAb levels suggests that NPT088 does not reduce brain
Ab by acting as a peripheral sink or by producing monomer
Ab. Although more characterization of the mechanism of
action of NPT088 in vivo is needed, our current
preclinical data are consistent with direct remodeling of
fibrillar deposits accompanied by microglia uptake of
NPT088:Ab aggregate complexes as a potential clearance
mechanism.
P5 .15). Data fromWTmice are shown for comparison. N5 2 (WT), 16 (Tg-PBS), 14 (Tg-NPT088), 13 (Tg-Time 0). One significant outlier (Grubb’s test) was
excluded from analyses (Tg-PBS). (F) The area of thioS-positive deposits was quantified from 2 sections per mouse in a defined region of interest with a fixed
area (w0.19 mm2) in sagittal sections of the parietal cortex, dorsal to hippocampus. A significant increase in thioS staining was observed over the course of the
study (q47 5 4.9, P , .0001). Treatment with NPT088 significantly reduced thioS staining in parietal cortex (q47 5 2.3, P 5 .045). N 5 19 (Tg-PBS), 18
(Tg-NPT088), 13 (Tg-Time 0). (G) Limb clasping was assessed during week 4 of dosing. rTg4510 mice receiving PBS exhibited significantly more severe
limb clasping relative to rTg4510 mice assessed at the beginning of the study (q50 5 2.7, P 5 .02). Mice treated with NPT088 exhibited a trend for reduced
limb clasping (q50 5 1.8, P 5 .13). N 5 20 (Tg-PBS), 20 (Tg-NPT088), 13 (Tg-Time 0). (H) rTg4510 mice that were treated with NPT088 exhibited signif-
icantly better performance in the novel object recognition test compared to mice that received PBS (t5 2, df5 21,P5 .03). N5 14 (Tg-PBS), 12 (Tg-NPT088).
In all panels, asterisks indicate significant difference from Tg-PBS.
=
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Ab represents a major component of the early pathology
associated with AD; however, accumulation of hyperphos-
phorylated tau-containing NFT pathology appears to be a
better correlate of cognitive impairment [48–52]. In AD,
tau pathology progresses in a stereotypical manner with
first lesions appearing in the locus coeruleus, basal
forebrain, and entorhinal cortex from where they appear to
spread to the hippocampus and neocortex [53]. There is
growing evidence that suggests that this spread of pathology
involves escape of tau aggregates from the diseased neurons
to the extracellular space, which infects neighboring neurons
[54,55]. This mode of cell-to-cell transmission is similar to
transmission of misfolded prion protein in transmissible
spongiform encephalopathies.
Cell culture models recapitulate the seeding and prion-
like transmission by tau aggregates [56]. Preliminary studies
from our laboratory show that preformed fibrils made from
synthetic peptides of the MTBR region can induce phos-
phorylation and recruitment of soluble tau into NFT-like ag-
gregates (Supplementary Fig. 2). Furthermore, NPT088 can
bind these transmission-competent fibrils with high affinity
and remodel them into nonfibrous conformers
(Supplementary Fig. 2C). Consistent with these cell culture
experiments, we show that NPT088 treatment produces
robust efficacy on neuropathologic and functional endpoints
in rTg4510 mice (Fig. 5) and can decrease brain atrophy in
older rTg4510 mice with severe brain pathology (Fig. 6).
Other studies have demonstrated that passive immuniza-
tion against p-tau containing epitopes or tau oligomers in
AD mouse models significantly reverses tau-related neuro-
pathology and behavioral abnormalities [30,57–65].
Although these results are promising, it has yet to be
determined which species of tau (i.e., monomer, oligomer,
fibrillar) or which potential p-tau epitopes [66] should be tar-
geted by immunotherapeutic approaches to exhibit signifi-
cant clinical efficacy. Our data suggest that binding to
monomeric tau is unnecessary for efficacy and further sug-
gest that targeting oligomeric and/or fibrous species of tau
is sufficient for slowing progression of tauopathy in vivo.
Although it is possible that tau-directed therapeutics will
yield significant functional improvement in clinical trials, as
suggested by phase II results of a tau aggregation inhibitor
[9], no phase III results of the tau immunotherapeutic class
have been reported. In AD patients, Ab and tau pathologies
appear to be nonoverlapping, both temporally and anatomi-
cally [67,68], suggesting distinct pathologic mechanisms.
Moreover, recent studies suggest that extracellular tau
increases Ab production [69] and that in the presence of Ab
pathology, the effect of tau immunotherapies is transient
[65]. Therefore, therapeutic approaches that focus on a single
pathologymay fail to adequately treat AD, especially in more
advanced stages of the disease [3]. NPT088 is a single thera-
peutic candidate that exhibits significant activity on both Ab
and tau, and this activity has been measured both in vitro
[14] and in preclinical AD models, which represents a poten-
tial advantage for translation of preclinical efficacy.
NPT088 is a unique therapeutic candidate for neurode-
generative disorders that involve accumulation of misfolded
protein aggregates. Systemic administration of NPT088 im-
proves cognition, decreases pathologic protein loads, and re-
duces neuropathology in both Ab and tau-based transgenic
mouse models.
Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.trci.2016.06.004.
RESEARCH IN CONTEXT
1. Systematic review: PubMed query (“passive immu-
nization”) AND (Abeta OR tau) AND (mouse)
NOT (review). Screening of titles and abstracts iden-
tified 98 relevant articles. Collectively, findings indi-
cate antibodies reduce pathology and improve
cognition only in mouse models that express the spe-
cific antigen.
2. Interpretation: Our findings that a fusion protein
bivalent for a general amyloid interaction motif
(GAIM) reduces pathology and improves cognitive
and motor endpoints in transgenic mouse models of
either aberrant Ab or tau accumulation establish
GAIM-based therapeutics as a novel strategy tar-
geting misfolded protein aggregates for treatment of
Alzheimer’s disease.
3. Future directions: Proof-of-concept and proof-of-
mechanism studies in patients.
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